Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 18: 984-986, 1972;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jähnchen, E.
Right arrow Articles by Levy, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jähnchen, E.
Right arrow Articles by Levy, G.

Clinical Chemistry, Vol 18, 984-986, Copyright © 1972 by the American Association for Clinical Chemistry

Determination of Phenylbutazone in Plasma

Eberhard Jähnchen 1 and Gerhard Levy 1

1 Department of Pharmaceutics, School of Pharmacy, State University of New York at Buffalo, Buffalo, N. Y. 14214.

The permanganate oxidation method for the spectrophotometric determination of phenylbutazone has been modified and optimized to permit precise assays of phenylbutazone in small plasma samples. The assay is not affected by the presence of p-hydroxyphenylbutazone, the major metabolite of phenylbutazone. Weak bases are removed in the initial extraction procedure, and weak acids such as phenobarbital, warfarin, diphenylhydantoin, salicylic acid, and sulfadiazine do not interfere in the assay.

Submitted on May 29, 1972
Accepted on July 4, 1972






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1972 by the American Association for Clinical Chemistry.